MAIA Biotechnology, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $83.9M
- Price
- $1.39
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.81%
- Volume
- 337.2K
About
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Quick stats
Shares outstanding60.8M
Computed float42.2M
Float / shares69.4%
Cash runway (months)15
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001878313
Websitehttps://www.MAIABiotech.com
AI Summary
AI-generated1/17
majorbullishclinical trial
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
MAIA Biotechnology reported positive interim efficacy data from the Part C expansion of its Phase 2 THIO-101 trial evaluating ateganosine in third-line NSCLC. The data showed a disease control rate of 90.5% in the evaluable population, significantly outperforming the approximate 25-35% rate associated with current chemotherapy treatments.
These results align with previously reported signals from earlier trial parts, maintaining high efficacy despite a more heavily pre-treated patient population in this cohort.
The company noted that treatment with ateganosine followed by cemiplimab has demonstrated an acceptable safety profile to date.